Johnson & Johnson Q1 Sales Rise 9.9% to $24.1 Billion on Oncology Growth
Johnson & Johnson posted Q1 sales of $24.1 billion, up 9.9% year-over-year, delivering operational growth of 6.4% and adjusted EPS of $2.70, beating forecasts. Innovative medicines sales rose 11.2% to $15.4 billion, driven by oncology therapies that generated $6.97 billion, while full-year growth guidance was increased to 5.6%–6.6%.
1. Q1 Financial Performance
Johnson & Johnson achieved Q1 sales of $24.1 billion, marking a 9.9% increase from the prior year. Operational growth reached 6.4%, and adjusted earnings per share were $2.70, surpassing analyst forecasts by two cents.
2. Innovative Medicines and Oncology Drivers
The Innovative Medicines segment delivered $15.4 billion in sales, up 11.2% year-over-year, led by oncology therapies. Darzalex and Carvykti collectively generated $6.97 billion, while neuroscience and immunology products also contributed to segment gains.
3. Full-Year Outlook and Icotyde Prospects
Management raised the 2026 operational sales growth outlook to a range of 5.6%–6.6%, up from 5.4%–6.4%. The upcoming launch of Icotyde, J&J’s IL-23 plaque psoriasis pill, is projected to reach $4.4 billion in global sales by 2032, offsetting biosimilar pressures on Stelara.